Article info
PDFInflammatory bowel disease
Original article
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
- Correspondence to Dr Shomron Ben-Horin, Gastroenterology Department, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel; shomron.benhorin{at}gmail.com
Citation
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Publication history
- Received February 3, 2015
- Revised March 23, 2015
- Accepted March 28, 2015
- First published April 20, 2015.
Online issue publication
June 03, 2016
Article Versions
- Previous version (3 June 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/